Practical considerations in the use of regorafenib in metastatic colorectal cancer
Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, reg...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Sprog: | English |
| Udgivet: |
SAGE Publishing
2020-10-01
|
| Serier: | Therapeutic Advances in Medical Oncology |
| Online adgang: | https://doi.org/10.1177/1758835920956862 |